Altered metabolism plays a central role in malignancy and has recently been named an emerging hallmark of cancer. Acute myeloid leukemia (AML) utilizes altered metabolism to maximize cell growth and survival. The interest in cancer cell metabolism has led to the development of novel therapies that target metabolic pathways. CPI-613 is a novel agent that targets the TCA cycle currently under development for the treatment of AML. How AML cells alter their metabolic pathways in response to chemotherapy or metabolically targeted agents like CPI-613 is not currently known. We hypothesize that AML cells following treatment with chemotherapy will up-regulate energy generation through the TCA cycle, glycolysis and autophagy and further that inhibition of one of these pathways will shift energy production to the other two.
The aims of this proposal are 1) determine the role of the master metabolic regulator AMPK in response to inhibition of the TCA cycle with the novel agent CPI-613, 2) determine the contribution of glycolysis and autophagy as alternative energy pathways when the TCA cycle is inhibited and 3) determine the changes in AML cell metabolism in response to standard chemotherapy agents. The results from this study will 1) uncover the role of AMPK in coordinating energy production following inhibition of the TCA cycle, 2) establish the role of glycolysis and autophagy as escape pathways for energy generation when the TCA cycle is inhibited and 3) demonstrate that AML cells up-regulate TCA cycle activity, glycolysis and autophagy following treatment with chemotherapy. These results have direct clinical implications. The TCA cycle inhibitor CPI-613 is under clinical development, the autophagy inhibitor chloroquine is FDA approved and the glycolysis inhibitor 2-deoxyglucose is under development. The proposed studies will assist in the development of novel treatment strategies for AML.
Acute myeloid leukemia uses altered metabolism to maximize cell growth and survival. This proposal will determine how AML cells coordinate the activity of multiple metabolic pathways to survive treatment with chemotherapy or inhibitors of mitochondrial metabolism.
|Pardee, Timothy S; Anderson, Rebecca G; Pladna, Kristin M et al. (2018) A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res 24:2060-2073|
|Alistar, Angela; Morris, Bonny B; Desnoyer, Rodwige et al. (2017) Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol 18:770-778|
|Rodman, C; Almeida-Porada, G; George, S K et al. (2017) In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells. Leukemia 31:1398-1407|
|Ahmed, Tamjeed; Koch, Abby L; Isom, Scott et al. (2017) Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit. Leuk Res 62:51-55|
|Klepin, Heidi D; Tooze, Janet A; Pardee, Timothy S et al. (2016) Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia. J Am Geriatr Soc 64:1988-1995|
|Gmeiner, William H; Debinski, Waldemar; Milligan, Carol et al. (2016) The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Future Oncol 12:2009-20|
|Lycan, Thomas W; Pardee, Timothy S; Petty, William J et al. (2016) A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PLoS One 11:e0164244|